Sarcoidosis
Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antig...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Valeyre, Dominique [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Umfang: |
13 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Effects of shape functions on flexural–torsional buckling of fixed circular arches - Dou, Chao ELSEVIER, 2013, London [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:383 ; year:2014 ; number:9923 ; day:29 ; month:03 ; pages:1155-1167 ; extent:13 |
| Links: |
|---|
| DOI / URN: |
10.1016/S0140-6736(13)60680-7 |
|---|
| Katalog-ID: |
ELV022393102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022393102 | ||
| 003 | DE-627 | ||
| 005 | 20230625135409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(13)60680-7 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014002000011.pica |
| 035 | |a (DE-627)ELV022393102 | ||
| 035 | |a (ELSEVIER)S0140-6736(13)60680-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 690 |q VZ |
| 084 | |a 38.38 |2 bkl | ||
| 084 | |a 56.20 |2 bkl | ||
| 084 | |a 56.11 |2 bkl | ||
| 100 | 1 | |a Valeyre, Dominique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sarcoidosis |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 13 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. | ||
| 520 | |a Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. | ||
| 700 | 1 | |a Prasse, Antje |4 oth | |
| 700 | 1 | |a Nunes, Hilario |4 oth | |
| 700 | 1 | |a Uzunhan, Yurdagul |4 oth | |
| 700 | 1 | |a Brillet, Pierre-Yves |4 oth | |
| 700 | 1 | |a Müller-Quernheim, Joachim |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Dou, Chao ELSEVIER |t Effects of shape functions on flexural–torsional buckling of fixed circular arches |d 2013 |g London [u.a.] |w (DE-627)ELV007685041 |
| 773 | 1 | 8 | |g volume:383 |g year:2014 |g number:9923 |g day:29 |g month:03 |g pages:1155-1167 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0140-6736(13)60680-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-GEO | ||
| 936 | b | k | |a 38.38 |j Seismologie |q VZ |
| 936 | b | k | |a 56.20 |j Ingenieurgeologie |j Bodenmechanik |q VZ |
| 936 | b | k | |a 56.11 |j Baukonstruktion |q VZ |
| 951 | |a AR | ||
| 952 | |d 383 |j 2014 |e 9923 |b 29 |c 0329 |h 1155-1167 |g 13 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
d v dv |
|---|---|
| matchkey_str |
valeyredominiqueprasseantjenuneshilariou:2014----:aci |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
38.38 56.20 56.11 |
| publishDate |
2014 |
| allfields |
10.1016/S0140-6736(13)60680-7 doi GBVA2014002000011.pica (DE-627)ELV022393102 (ELSEVIER)S0140-6736(13)60680-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Valeyre, Dominique verfasserin aut Sarcoidosis 2014transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Prasse, Antje oth Nunes, Hilario oth Uzunhan, Yurdagul oth Brillet, Pierre-Yves oth Müller-Quernheim, Joachim oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 https://doi.org/10.1016/S0140-6736(13)60680-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 383 2014 9923 29 0329 1155-1167 13 045F 610 |
| spelling |
10.1016/S0140-6736(13)60680-7 doi GBVA2014002000011.pica (DE-627)ELV022393102 (ELSEVIER)S0140-6736(13)60680-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Valeyre, Dominique verfasserin aut Sarcoidosis 2014transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Prasse, Antje oth Nunes, Hilario oth Uzunhan, Yurdagul oth Brillet, Pierre-Yves oth Müller-Quernheim, Joachim oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 https://doi.org/10.1016/S0140-6736(13)60680-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 383 2014 9923 29 0329 1155-1167 13 045F 610 |
| allfields_unstemmed |
10.1016/S0140-6736(13)60680-7 doi GBVA2014002000011.pica (DE-627)ELV022393102 (ELSEVIER)S0140-6736(13)60680-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Valeyre, Dominique verfasserin aut Sarcoidosis 2014transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Prasse, Antje oth Nunes, Hilario oth Uzunhan, Yurdagul oth Brillet, Pierre-Yves oth Müller-Quernheim, Joachim oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 https://doi.org/10.1016/S0140-6736(13)60680-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 383 2014 9923 29 0329 1155-1167 13 045F 610 |
| allfieldsGer |
10.1016/S0140-6736(13)60680-7 doi GBVA2014002000011.pica (DE-627)ELV022393102 (ELSEVIER)S0140-6736(13)60680-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Valeyre, Dominique verfasserin aut Sarcoidosis 2014transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Prasse, Antje oth Nunes, Hilario oth Uzunhan, Yurdagul oth Brillet, Pierre-Yves oth Müller-Quernheim, Joachim oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 https://doi.org/10.1016/S0140-6736(13)60680-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 383 2014 9923 29 0329 1155-1167 13 045F 610 |
| allfieldsSound |
10.1016/S0140-6736(13)60680-7 doi GBVA2014002000011.pica (DE-627)ELV022393102 (ELSEVIER)S0140-6736(13)60680-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Valeyre, Dominique verfasserin aut Sarcoidosis 2014transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. Prasse, Antje oth Nunes, Hilario oth Uzunhan, Yurdagul oth Brillet, Pierre-Yves oth Müller-Quernheim, Joachim oth Enthalten in Elsevier Dou, Chao ELSEVIER Effects of shape functions on flexural–torsional buckling of fixed circular arches 2013 London [u.a.] (DE-627)ELV007685041 volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 https://doi.org/10.1016/S0140-6736(13)60680-7 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO 38.38 Seismologie VZ 56.20 Ingenieurgeologie Bodenmechanik VZ 56.11 Baukonstruktion VZ AR 383 2014 9923 29 0329 1155-1167 13 045F 610 |
| language |
English |
| source |
Enthalten in Effects of shape functions on flexural–torsional buckling of fixed circular arches London [u.a.] volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 |
| sourceStr |
Enthalten in Effects of shape functions on flexural–torsional buckling of fixed circular arches London [u.a.] volume:383 year:2014 number:9923 day:29 month:03 pages:1155-1167 extent:13 |
| format_phy_str_mv |
Article |
| bklname |
Seismologie Ingenieurgeologie Bodenmechanik Baukonstruktion |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| authorswithroles_txt_mv |
Valeyre, Dominique @@aut@@ Prasse, Antje @@oth@@ Nunes, Hilario @@oth@@ Uzunhan, Yurdagul @@oth@@ Brillet, Pierre-Yves @@oth@@ Müller-Quernheim, Joachim @@oth@@ |
| publishDateDaySort_date |
2014-01-29T00:00:00Z |
| hierarchy_top_id |
ELV007685041 |
| dewey-sort |
3610 |
| id |
ELV022393102 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022393102</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625135409.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S0140-6736(13)60680-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014002000011.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022393102</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0140-6736(13)60680-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.20</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Valeyre, Dominique</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sarcoidosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prasse, Antje</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nunes, Hilario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uzunhan, Yurdagul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brillet, Pierre-Yves</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Müller-Quernheim, Joachim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Dou, Chao ELSEVIER</subfield><subfield code="t">Effects of shape functions on flexural–torsional buckling of fixed circular arches</subfield><subfield code="d">2013</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV007685041</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:383</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:9923</subfield><subfield code="g">day:29</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:1155-1167</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S0140-6736(13)60680-7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GEO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.38</subfield><subfield code="j">Seismologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.20</subfield><subfield code="j">Ingenieurgeologie</subfield><subfield code="j">Bodenmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.11</subfield><subfield code="j">Baukonstruktion</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">383</subfield><subfield code="j">2014</subfield><subfield code="e">9923</subfield><subfield code="b">29</subfield><subfield code="c">0329</subfield><subfield code="h">1155-1167</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Valeyre, Dominique |
| spellingShingle |
Valeyre, Dominique ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 Sarcoidosis |
| authorStr |
Valeyre, Dominique |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007685041 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl Sarcoidosis |
| topic |
ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 |
| topic_unstemmed |
ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 |
| topic_browse |
ddc 610 ddc 690 bkl 38.38 bkl 56.20 bkl 56.11 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a p ap h n hn y u yu p y b pyb j m q jmq |
| hierarchy_parent_title |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| hierarchy_parent_id |
ELV007685041 |
| dewey-tens |
610 - Medicine & health 690 - Building & construction |
| hierarchy_top_title |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007685041 |
| title |
Sarcoidosis |
| ctrlnum |
(DE-627)ELV022393102 (ELSEVIER)S0140-6736(13)60680-7 |
| title_full |
Sarcoidosis |
| author_sort |
Valeyre, Dominique |
| journal |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| journalStr |
Effects of shape functions on flexural–torsional buckling of fixed circular arches |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
1155 |
| author_browse |
Valeyre, Dominique |
| container_volume |
383 |
| physical |
13 |
| class |
610 610 DE-600 690 VZ 38.38 bkl 56.20 bkl 56.11 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Valeyre, Dominique |
| doi_str_mv |
10.1016/S0140-6736(13)60680-7 |
| dewey-full |
610 690 |
| title_sort |
sarcoidosis |
| title_auth |
Sarcoidosis |
| abstract |
Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. |
| abstractGer |
Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. |
| abstract_unstemmed |
Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-GEO |
| container_issue |
9923 |
| title_short |
Sarcoidosis |
| url |
https://doi.org/10.1016/S0140-6736(13)60680-7 |
| remote_bool |
true |
| author2 |
Prasse, Antje Nunes, Hilario Uzunhan, Yurdagul Brillet, Pierre-Yves Müller-Quernheim, Joachim |
| author2Str |
Prasse, Antje Nunes, Hilario Uzunhan, Yurdagul Brillet, Pierre-Yves Müller-Quernheim, Joachim |
| ppnlink |
ELV007685041 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/S0140-6736(13)60680-7 |
| up_date |
2024-07-06T21:52:51.978Z |
| _version_ |
1803868199430651904 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022393102</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625135409.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S0140-6736(13)60680-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014002000011.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022393102</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0140-6736(13)60680-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">38.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.20</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">56.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Valeyre, Dominique</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sarcoidosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sarcoidosis is a systemic disease of unknown cause that is characterised by the formation of immune granulomas in various organs, mainly the lungs and the lymphatic system. Studies show that sarcoidosis might be the result of an exaggerated granulomatous reaction after exposure to unidentified antigens in individuals who are genetically susceptible. Several new insights have been made, particularly with regards to the diagnosis and care of some important manifestations of sarcoidosis. The indications for endobronchial ultrasound in diagnosis and for PET in the assessment of inflammatory activity are now better specified. Recognition of unexplained persistent disabling symptoms, fatigue, small-fibre neurological impairment, cognitive failure, and changes to health state and quality of life, has improved. Mortality in patients with sarcoidosis is higher than that of the general population, mainly due to pulmonary fibrosis. Predicted advances for the future are finding the cause of sarcoidosis, and the elucidation of relevant biomarkers, reliable endpoints, and new efficient treatments, particularly in patients with refractory sarcoidosis, lung fibrosis, and those with persistent disabling symptoms.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prasse, Antje</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nunes, Hilario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uzunhan, Yurdagul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brillet, Pierre-Yves</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Müller-Quernheim, Joachim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Dou, Chao ELSEVIER</subfield><subfield code="t">Effects of shape functions on flexural–torsional buckling of fixed circular arches</subfield><subfield code="d">2013</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV007685041</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:383</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:9923</subfield><subfield code="g">day:29</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:1155-1167</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S0140-6736(13)60680-7</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GEO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">38.38</subfield><subfield code="j">Seismologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.20</subfield><subfield code="j">Ingenieurgeologie</subfield><subfield code="j">Bodenmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">56.11</subfield><subfield code="j">Baukonstruktion</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">383</subfield><subfield code="j">2014</subfield><subfield code="e">9923</subfield><subfield code="b">29</subfield><subfield code="c">0329</subfield><subfield code="h">1155-1167</subfield><subfield code="g">13</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4021845 |